We look forward to evaluating dostarlimab-gxly in certain colorectal cancers in our ongoing AZUR-1 and AZUR-2 registrational studies." GSK said the patients in the study did not experience adverse ...

In what can be termed a never-seen-before medical miracle, a small group of people with colorectal cancer achieved 100% ...

Our colorectal trial, supported by F ... in a Phase 1b/2 trial combining LIXTE's LB-100 with GSK's immunotherapy, dostarlimab-gxly, targeting ovarian clear cell carcinoma. Dosing of the first ...

Detailed price information for Lixte Biotech Hlds (LIXT-Q) from The Globe and Mail including charting and trades.